For example, enzootic strains of Y. pestis isolated from voles in Transcaucasian Highland and Mountain Dagestan are missing the pPst plasmid [61], the most prevalent target for diagnostic PCR.
A significant proportion of hypertensive subjects in primary care had documented associated target organ damage, with left ventricular hypertrophy being the most prevalent target organ damage.
If the primary target of chronic exposure and toxicity is the liver, the second most prevalent target is the kidneys, followed by the reproductive organs, the brain, hematopoietic tissues, and bone.
Currently, the most prevalent targeted therapies in RA are the anti-tumor necrosis factor (anti-TNF) agents infliximab, adalimumab, and etanercept, which act to neutralize the signaling of this pro-inflammatory cytokine [ 1– 4].
This study sought to identify the most prevalent molecular targets in gastric cancer and to elucidate systematic patterns of exclusivity and co-occurrence among these targets, through comprehensive genomic analysis of a large panel of gastric cancers.
17 In this study, we sought to identify the most prevalent molecular targets in gastric cancer and to elucidate their ITR.
22 27 Using GISTIC, we identified 22 recurrently altered regions in gastric cancer that are likely to represent the most prevalent molecular targets.
Here we report a high-resolution genomic analysis of a large cohort of gastric cancer primary tumours and cell lines delineating the most prevalent molecular targets in this disease.
In this system, the presynaptic GABAergic axons originated from embryonic rat basal ganglia medium spiny neurones, whereas their most prevalent postsynaptic targets, i.e. α1/β2/γ2-GABAARs, were expressed constitutively in a stably transfected human embryonic kidney 293 (HEK293) cell line.
As such, a comprehensive and unbiased survey to identify the most prevalent molecular targets in gastric cancer could facilitate many aspects of gastric cancer translational research, for example, in focusing clinical trials efforts on those therapies that might benefit the greatest numbers of gastric cancer patients.
